Ifinatamab Biosimilar – Anti-CD276 mAb – Research Grade

Description of Ifinatamab Biosimilar - Anti-CD276 mAb - Research Grade

Introduction

Ifinatamab Biosimilar, also known as Anti-CD276 mAb, is a research grade monoclonal antibody that has shown promising results in the treatment of various cancers. This antibody specifically targets the CD276 protein, which is overexpressed in many types of cancer cells. In this article, we will delve into the structure, activity, and potential applications of Ifinatamab Biosimilar.

Structure of Ifinatamab Biosimilar

Ifinatamab Biosimilar is a monoclonal antibody, meaning it is derived from a single type of immune cell. It is a fully humanized antibody, meaning it is made up of human proteins and is less likely to cause an immune response in patients. The antibody is composed of two identical heavy chains and two identical light chains, which are connected by disulfide bonds. These chains form the Y-shaped structure commonly seen in antibodies.

The variable regions of Ifinatamab Biosimilar are responsible for its specificity towards the CD276 protein. These regions, also known as the antigen-binding regions, are located at the tips of the Y-shaped structure and are highly variable between different antibodies. The constant regions of the antibody are responsible for its effector functions, such as binding to immune cells and activating them to attack cancer cells.

Activity of Ifinatamab Biosimilar

The primary activity of Ifinatamab Biosimilar is its ability to bind to the CD276 protein. CD276, also known as B7-H3, is a cell surface protein that is overexpressed in many types of cancer cells. This protein plays a role in promoting cancer cell growth and survival, making it an attractive target for cancer treatment.

When Ifinatamab Biosimilar binds to CD276, it blocks its activity and prevents it from promoting cancer cell growth. This can lead to the death of cancer cells and inhibit tumor growth. Additionally, the binding of Ifinatamab Biosimilar to CD276 can also activate the immune system to attack cancer cells, further enhancing its anti- cancer activity.

Applications of Ifinatamab Biosimilar

The primary application of Ifinatamab Biosimilar is in the treatment of cancer. It has shown promising results in preclinical studies and is currently being evaluated in clinical trials for various types of cancer, including lung cancer, breast cancer, and ovarian cancer. The ability of Ifinatamab Biosimilar to specifically target CD276 makes it a potentially effective and safe treatment option for these cancers.

Furthermore, Ifinatamab Biosimilar may also have potential applications in immunotherapy. By activating the immune system to attack cancer cells, it can be used in combination with other immunotherapies to enhance their efficacy. This could potentially lead to more effective and personalized treatments for cancer patients.

Conclusion

Ifinatamab Biosimilar, also known as Anti-CD276 mAb, is a research grade monoclonal antibody that specifically targets the CD276 protein. Its structure, activity, and potential applications make it a promising candidate for the treatment of various types of cancer. As research and clinical trials continue, Ifinatamab Biosimilar may play a crucial role in improving outcomes for cancer patients and advancing the field of cancer treatment.

Ifinatamab Biosimilar - Anti-CD276 mAb binds to CD276 Recombinant Protein in indirect ELISA Assay

Immobilized CD276 Recombinant Protein (cat. No.PX-P4125) at 0.5µg/mL (100µL/well) can bind to Ifinatamab Biosimilar - Anti-CD276 mAb (cat. No.PX-TA1847) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450